	US 12,491,274 B2
	Radioconjugates targeting CD33 in the treatment of sarcomas
Mary M. Chen, Hoboken, NJ (US); Avinash Desai, Ringoes, NJ (US); Dale L. Ludwig, Rockaway, NJ (US); and Mark Berger, New York, NY (US)
Filed by ACTINIUM PHARMACEUTICALS, INC., New York, NY (US)
Filed on Aug. 26, 2022, as Appl. No. 17/822,701.
Application 17/822,701 is a continuation in part of application No. 17/883,434, filed on Aug. 8, 2022.
Application 17/883,434 is a continuation in part of application No. 17/532,919, filed on Nov. 22, 2021.
Claims priority of provisional application 63/230,431, filed on Aug. 6, 2021.
Prior Publication US 2023/0092668 A1, Mar. 23, 2023
Int. Cl. A61K 51/10 (2006.01); A61K 45/06 (2006.01)

CPC A61K 51/1027 (2013.01) [A61K 45/06 (2013.01)]

2 Claims

1. A method for treating a sarcoma in a human subject, comprising administering a therapeutically effective amount of a radiolabeled anti-CD33 antibody to a human subject in need of treatment for a sarcoma,

wherein the radiolabeled anti-CD33 antibody comprises ²²⁵Ac-labeled conjugate of p-SCN-Bn-DOTA and lintuzumab, and

wherein the sarcoma is osteosarcoma, dermatofibrosarcoma protuberans (DFSP), fibrosarcoma (fibroblastic sarcoma), chondrosarcoma, Ewing's sarcoma, Kaposi's sarcoma, rhabdomyosarcoma, liposarcoma, synovial sarcoma, pleomorphic sarcoma, gastrointestinal stromal tumor, leiomyosarcoma, or angiosarcoma.